ID: ALA4874471
Chembl Id: CHEMBL4874471
PubChem CID: 164627868
Max Phase: Preclinical
Molecular Formula: C203H316N56O63S2
Molecular Weight: 4613.22
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC[C@H](NC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O
Standard InChI: InChI=1S/C203H316N56O63S2/c1-19-103(10)159(192(311)245-136(77-101(6)7)198(317)259-74-46-55-144(259)199(318)258-73-45-54-143(258)190(309)256-164(111(18)267)196(315)244-135(87-150(209)274)181(300)250-158(102(8)9)191(310)219-90-154(278)229-137(92-260)184(303)242-133(85-148(207)272)182(301)255-163(110(17)266)195(314)233-124(165(210)284)78-114-58-60-117(268)61-59-114)251-189(308)142-53-44-72-257(142)155(279)91-220-169(288)127(79-112-47-36-34-37-48-112)236-179(298)131(83-146(205)270)240-180(299)132(84-147(206)271)241-185(304)138(93-261)247-186(305)139(94-262)246-178(297)130(82-116-89-216-98-222-116)239-177(296)129(81-115-88-215-97-221-115)238-175(294)126(76-100(4)5)235-176(295)128(80-113-49-38-35-39-50-113)237-173(292)121(65-69-157(282)283)230-166(285)104(11)223-174(293)125(75-99(2)3)234-171(290)119(52-43-71-218-203(213)214)231-172(291)120(62-66-145(204)269)232-194(313)161(108(15)264)252-167(286)105(12)224-187(306)140-95-323-324-96-141(188(307)243-134(86-149(208)273)183(302)254-160(107(14)263)193(312)225-106(13)168(287)253-162(109(16)265)197(316)249-140)248-170(289)118(51-42-70-217-202(211)212)226-152(276)67-63-123(201(321)322)228-153(277)68-64-122(200(319)320)227-151(275)56-40-32-30-28-26-24-22-20-21-23-25-27-29-31-33-41-57-156(280)281/h34-39,47-50,58-61,88-89,97-111,118-144,158-164,260-268H,19-33,40-46,51-57,62-87,90-96H2,1-18H3,(H2,204,269)(H2,205,270)(H2,206,271)(H2,207,272)(H2,208,273)(H2,209,274)(H2,210,284)(H,215,221)(H,216,222)(H,219,310)(H,220,288)(H,223,293)(H,224,306)(H,225,312)(H,226,276)(H,227,275)(H,228,277)(H,229,278)(H,230,285)(H,231,291)(H,232,313)(H,233,314)(H,234,290)(H,235,295)(H,236,298)(H,237,292)(H,238,294)(H,239,296)(H,240,299)(H,241,304)(H,242,303)(H,243,307)(H,244,315)(H,245,311)(H,246,297)(H,247,305)(H,248,289)(H,249,316)(H,250,300)(H,251,308)(H,252,286)(H,253,287)(H,254,302)(H,255,301)(H,256,309)(H,280,281)(H,282,283)(H,319,320)(H,321,322)(H4,211,212,217)(H4,213,214,218)/t103-,104-,105-,106-,107+,108+,109+,110+,111+,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,158-,159-,160-,161-,162-,163-,164-/m0/s1
Standard InChI Key: YVBWVQLOARAVQL-IFFWLQTRSA-N
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 4613.22 | Molecular Weight (Monoisotopic): 4610.2686 | AlogP: | #Rotatable Bonds: |
| Polar Surface Area: | Molecular Species: | HBA: | HBD: |
| #RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
| Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
| 1. Kruse T, Hansen JL, Dahl K, Schäffer L, Sensfuss U, Poulsen C, Schlein M, Hansen AMK, Jeppesen CB, Dornonville de la Cour C, Clausen TR, Johansson E, Fulle S, Skyggebjerg RB, Raun K.. (2021) Development of Cagrilintide, a Long-Acting Amylin Analogue., 64 (15.0): [PMID:34288673] [10.1021/acs.jmedchem.1c00565] |
Source(1):
